

Ian Swan

Associate

swan.ian@dorsey.com

Washington, D.C. – 202.442.3503



Ian Swan defends technology and pharmaceutical clients in patent litigation and complex commercial disputes, translating dense scientific and technical subject matter into clear arguments that move cases toward resolution.

Ian brings that same precision to every stage of litigation — from early case strategy through dispositive motions — with a focus on matters where the science is as contested as the law. Ian is a Washington, D.C.-based associate whose practice centers on intellectual property (IP) litigation, with particular depth in patent disputes and technically complex commercial cases.

In patent litigation, Ian has represented technology companies and pharmaceutical manufacturers, working through the full arc of contested cases and negotiated resolutions. His experience also extends to products liability multidistrict litigation (MDL), where he has helped clients obtain dismissal of claims brought by multiple parties, including tribal entities and state governments.

Ian is committed to pro bono service, representing clients in civil rights and immigration matters.

Ian is a contributing author to *ANDA Litigation: Strategies for Pharmaceutical Patent Litigators*, Fourth Edition, and has published on topics including International Trade Commission (ITC) Section 337 proceedings, Chevron deference and its implications for U.S. Food and Drug Administration (FDA) regulatory authority, and evolving claim construction standards in Delaware IP courts.

Select Experience

Pharmaceutical Patent Litigation

- Represented a generic pharmaceutical manufacturer in Hatch-Waxman patent

Education

- Boston College Law School (J.D., 2023)
 - *cum laude*
- University of Massachusetts at Amherst (B.S., 2019)
 - Commonwealth Honors College Graduate

Bar Admissions

- District of Columbia
- Maryland

litigation, helping obtain a favorable settlement for the client.*

- Represented a pharmaceutical manufacturer in Hatch-Waxman patent litigation, helping obtain a favorable settlement and dismissal of all claims.*

Products Liability & Complex Commercial Litigation

- Represented a pharmaceutical manufacturer in products liability multidistrict litigation, helping obtain dismissal of claims asserted by numerous tribal entities and state governments.*

Pro Bono

- Represented a *pro bono* civil rights client in litigation against state prison officials, successfully defeating multiple motions to dismiss and a motion for summary judgment.*

* Experience occurred prior to joining Dorsey.

Court Admissions

- U.S. District Court for the District of Connecticut

Accolades

- Capitol *Pro Bono* Honor Roll, 2024

Legal Writings

- *Potential Shifts in Section 337 Precedent: What The Data Tells Us*, IP Watchdog (2024)
- *Chevron Deference on the Brink: Small Fish May Mean Big Changes for FDA*, Food & Drug Law Institute Spring 2024 Update
- *Del. IP Ruling May Mark Limitation-By-Limitation Analysis Shift*, Law360 (2024)
- *Chapter 12: Discovery, ANDA Litigation: Strategies for Pharmaceutical Patent Litigators*, Fourth Edition